General Information

Provenge Comes Closer to European Union Approval for Men with Advanced Prostate Cancer

It was announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that PROVENGE® (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or Sipuleucel-T) be granted marketing authorization in the European Union (EU), for the treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) [...]

By Malecare|2013-06-28T09:05:09-04:00June 28th, 2013|Advanced Prostate Cancer, CHMP, Drugs & Treatments, General Information, Provenge, Uncategorized, Understanding APC, vaccines|2 Comments

On the Horizon – Many More Novel Drugs for the Treatment of Advanced Prostate Cancer

There have been many potential targets identified for the treatment of advanced prostate cancer. Many of these targets are being actively explored with clinical trials designed to test some inhibitors of the targets. Antisense oligonucleotides (OGX-011) targets clusterin, a chaperone protein and OGX-427 which targets heat-shock protein 27 are among the inhibitors being evaluated. OGX-011 [...]

By Malecare|2017-10-19T10:49:43-04:00June 27th, 2013|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Combination Therapy, Custirsen, Drugs & Treatments, General Information, On The Horizon, Tasquinimod (TASQ), Uncategorized, Understanding APC|0 Comments

PET/MR Imaging More Efficacious for Mapping Recurrent Prostate Cancer

Approximately one third of all men diagnosed and treated for prostate cancer will experience a recurrence of their prostate cancer! This is a shocking number, but it is a true number. It does not matter what the treatment a man has, the statistic holds up across all treatments. The first sign of a problem, a [...]

By Malecare|2020-02-04T10:44:08-05:00June 18th, 2013|adjuvant therapy, Advanced Prostate Cancer, Bio Chemical Recurrence, Choline C11, General Information, Research, salvage therapy, Uncategorized, Understanding APC|0 Comments

DOD PCRP Gets Funded for the 2014 Budget Year

I have often discussed the importance of the Prostate Cancer Research Program (PCRP), which is a part of the Department of Defense (DOD) Medical Research Program. The program is geared to delivering funding for prostate cancer research that is translational, or will be quickly interpreted in the clinic. Like all other government funding it very [...]

By Malecare|2021-02-17T10:43:15-05:00June 14th, 2013|Advanced Prostate Cancer, Advocacy, DOD, Financial, General Information, Politics of Cancer, Research, Start A Cure, Uncategorized|0 Comments

Important – Read the Prescribing Information that Comes with Your Medications

The following is a post from Chuck Maack on the Advanced Prostate Cancer Internet support group: “It came to mind wondering how many patients and/or their caregivers prescribed Zytiga/abiraterone acetate have ever taken the important time to read all the details regarding the effects that may be experienced by patients and whether or not they [...]

By Malecare|2021-02-17T10:43:06-05:00May 23rd, 2013|Advanced Prostate Cancer, Drugs & Treatments, General Information, Prostate Ponderings, Uncategorized, Understanding APC|2 Comments

Announcing A New Research Platform – Start A Cure

The news is in, and it is bad. It is as bad as many of us feared. The National Institute of Health (NIH) has announced that their across-the-board budget sequester cuts are going to equal 1.71 billion dollars. The NIH is responsible for the majority of cancer research performed in the United States. For the [...]

By Malecare|2020-02-04T11:50:19-05:00May 21st, 2013|Advanced Prostate Cancer, Financial, General Information, Politics of Cancer, Research, Start A Cure, Uncategorized|4 Comments

Hopefully A Good Re-Start from Bayer Healthcare in Mending Their Ways & Building Trust with the Prostate Cancer Community

I want to share that I am hopeful that we have made progress with Bayer Healthcare and the issues I have written about surrounding the newly approved treatment for men with castrate resistant prostate cancer, Xofigo. I have shared that they failed to support the early access trials because of what they claimed were supply [...]

By Malecare|2017-10-19T10:49:48-04:00May 16th, 2013|Advanced Prostate Cancer, Alpharadin (radium-223), Drugs & Treatments, Early/Expanded Access Programs, General Information, Politics of Cancer, Uncategorized, Understanding APC, Xofigo|0 Comments

Ra 223 Dichloride (Xofigo®) Approved by the FDA

More great news for men with advanced prostate cancer that is castrate resistant and who also have symptomatic bone metastases and no known visceral metastatic disease. Today, Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has approved (radium Ra 223 dichloride). Xofigo (zo-FEE-go) is the first and only alpha particle-emitting radioactive therapeutic [...]

By Malecare|2013-05-15T13:31:11-04:00May 15th, 2013|Advanced Prostate Cancer, Alpharadin (radium-223), FDA, General Information, Uncategorized, Understanding APC, Xofigo|2 Comments

ADJUVANT AND SALVAGE RADIOTHERAPY AFTER PROSTATECTOMY: NEW ASTRO/AUA GUIDELINE

A joint task force composed of members from the American Urological Association (AUA) and the American Society for Radiation Oncology (ASTRO) has presented formal guidelines for the use of adjuvant and salvage radiation after a radical prostatectomy. To construct the Guideline they relied on a systematic review of the literature using the Pubmed, Embase and [...]

By Malecare|2020-02-04T11:56:34-05:00May 9th, 2013|adjuvant therapy, Advanced Prostate Cancer, AUA, Drugs & Treatments, General Information, Hormone Therapy, Radiotherapy, salvage therapy, Uncategorized, Understanding APC|2 Comments

The AUA Issues Specific Guidelines for the Treatment of Men with Castrate Resistant Prostate Cancer

There was a lot of interesting and important presentations at the recent American Urological Association meeting, however the one item that will have the most impact on men with advanced prostate cancer is the new guidelines that were proposed for the treatment of men with castrate resistant prostate cancer. The guidelines were organized by creating [...]

By Malecare|2020-02-04T10:48:43-05:00May 8th, 2013|2nd line hormone therapy, abiraterone acetate, Advanced Prostate Cancer, AUA, Chemo Therapy, Drugs & Treatments, enzalutamide, Enzalutamide (MDV-3100), General Information, How We Live, Prostate Ponderings, Provenge, Uncategorized, Understanding APC, vaccines|0 Comments